Differential response of tumor cells and normal fibroblasts to fractionated combined treatment with topotecan and ionizing radiation

International Journal of Radiation Biology

Volumn 78, Issue 2, 2002, Pages 125-132

  Ohneseit, P A ^a   Wildemann, A ^a   Herskind, C ^a   Bamberg, M ^a   Rodemann, H P ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TOPOTECAN;

ARTICLE; CELL SURVIVAL; CLONOGENIC ASSAY; COLONY FORMATION; DNA CLEAVAGE; DNA REPAIR; DOSE RESPONSE; DRUG EFFECT; FIBROBLAST; GLIOBLASTOMA; HUMAN; HUMAN CELL; IONIZING RADIATION; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; TUMOR CELL;

ANTINEOPLASTIC AGENTS; CELL SURVIVAL; CELLS, CULTURED; COMBINED MODALITY THERAPY; DNA TOPOISOMERASES, TYPE I; ENZYME INHIBITORS; FIBROBLASTS; HUMANS; NEOPLASMS; RADIATION, IONIZING; TIME FACTORS; TOPOTECAN; TUMOR CELLS, CULTURED;

EID: 0036155872     PISSN: 09553002     EISSN: None     Source Type: Journal    
DOI: 10.1080/09553000110090025     Document Type: Article

References (30)

1. Topotecan, a new active drug in the second line treatment of small cell lung cancer: A phase II study in patients with refractory and sensitive disease
2. Detection of P-glycoprotein in ovarian cancer: A molecular marker associated with multidrug-resistance
3. Down-regulation of topoisomerase I in mammalian cells following ionizing radiation
4. Inhibition of potentially lethal DNA damage repair in human tumor cells by β-lapachone, an activator of topoisomerase I
5. Posttreatment exposure to camptothecin enhances the lethal effects of x-rays on radioresistant human malignant melanoma cells
6. Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme
7. Mammalian DNA topoisomerase I mediates the enhancement of radiation cytotoxicity by camptothecin derivatives
8. Topotecan, an active drug in the second line treatment of epithelial ovarian cancer: Results of a large European phase II study
9. Resistance to multiple chemotherapeutic agents in human cancer cells
10. On the mechanism of topoisomerase I inhibition by camptothecin: Evidence for binding to an enzyme-DNA complex
11. Effects of camptothecin on the breakage and repair of DNA during the cell cycle
12. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin
13. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: Demonstration of tumor-type specificity and implications for cancer chemotherapy
14. Cell death induced by topoisomerase-targeted drugs: More questions than answers
15. The response of eukaryotic topoisomerases to DNA damage
16. Radiation enhancement by 9-aminocamptothecin: The effect of fractionation and timing of administration
17. Topotecan - A novel topoisomerase I inhibitor: Pharmacology and clinical experience
18. Concentration and timing dependence of lethality enhancement between Topotecan, a topoisomerase I inhibitor, and ionizing radiation
19. Radiation lethality enhancement with 9-aminocamptothecin: Comparison to other topoisomerase I inhibitors
20. Phase II study of topotecan with recurrent malignant glioma
21. Interaction of ionizing radiation with topotecan in two human tumor cell lines
22. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor Topotecan (SK&F 104864)
23. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme
24. Effects of uracil incorporation, DNA mismatches, and abasic sites on cleavage and religation activities of mammalian topoisomerase I
25. Phase I and pharmacological study of topotecan: A novel topoisomerase I inhibitor
26. Topotecan in combination chemotherapy
27. Topoisomerase inhibitors. A review of their therapeutic potential in cancer
28. Terminology in the description of drug-radiation interaction
29. Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity
30. DNA topoisomerases